The Journal of Practical Medicine >
Liraglutide ameliorates high glucose⁃induced endothelial cell injuryvia Nrf2
Received date: 2024-01-23
Online published: 2024-07-30
Objective This study aimed to investigate the effect and mechanism of Liraglutide on high glucose-induced vascular endothelial cell injury. Methods Human umbilical vein endothelial cells （HUVECs） were cultured and divided into 4 groups： control， high glucose stimulation （HG）， Liraglutide， and Liraglutide + HG group. ELISA was used to detect the secretion of inflammatory cytokines in each group， kits the levels of intracellular reactive oxygen species （ROS）， the activity of SOD2 and Gpx4，and the level of MDA， and Western blot and immun of luorescence method nuclear translocation of Nrf2. Results The HG groupexhibited a significantly higher levels of tumor necrosis factor （TNF?α）， interleukin （IL-1）， IL-6， as well as the levels of intracellular ROS and MDA， but less activity of SOD2 and Gpx4， less contents of NO， and less nuclear translocation of Nrf2， as compared with the control group. Compared with the HG group， the Liraglutide + HG grouppresented significantly higher levels of TNF?α， IL-1， and IL-6， but lower levels of intracellular ROS and MDA， less activities of SOD2 and Gpx4， less contents of NO and less nuclear translocation of Nrf2. Conclusion Liraglutide suppresses high glucose-induced endothelial cell injury by increasing the nuclear translocation of Nrf2.
Yunlong SUN , Zhe MENG , Xijia WANG , Lu. GAO . Liraglutide ameliorates high glucose⁃induced endothelial cell injuryvia Nrf2[J]. The Journal of Practical Medicine, 2024 , 40(15) : 2051 -2055 . DOI: 10.3969/j.issn.1006-5725.2024.15.002
| 1 | CESTA C E， ROTEM R， BATEMAN B T， et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy ［J］. JAMA Intern Med， 2024， 184（2）： 144-152. doi:10.1001/jamainternmed.2023.6663 |
| 2 | NEUEN B L， HEERSPINK H J L， VART P， et al. Estimated Lifetime Cardiovascular， Kidney， and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors， GLP-1 Receptor Agonists， and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria ［J］. Circulation， 2024， 149（6）： 450-462. doi:10.1161/circulationaha.123.067584 |
| 3 | ZHU Y， XIA X， HE Q， et al. Diabetes-associated neutrophil NETosis： pathogenesis and interventional target of diabetic complications ［J］. Front Endocrinol （Lausanne）， 2023， 14： 1202463. doi:10.3389/fendo.2023.1202463 |
| 4 | CYR A R， HUCKABY L V， SHIVA S S， et al. Nitric Oxide and Endothelial Dysfunction ［J］. Crit Care Clin， 2020， 36（2）： 307-321. doi:10.1016/j.ccc.2019.12.009 |
| 5 | ALMUTAIRI M， BATRAN RUSSHER J R AL. Glucagon-like peptide-1 receptor action in the vasculature ［J］. Peptides， 2019， 111： 26-32. doi:10.1016/j.peptides.2018.09.002 |
| 6 | ANDRIKOU E， TSIOUFIS C， ANDRIKOU I， et al. GLP-1 receptor agonists and cardiovascular outcome trials： An update ［J］. Hellenic J Cardiol， 2019， 60（6）： 347-351. doi:10.1016/j.hjc.2018.11.008 |
| 7 | LE Y， WEI R， YANG K， et al. Liraglutide ameliorates palmitate-induced oxidative injury in islet microvascular endothelial cells through GLP-1 receptor/PKA and GTPCH1/eNOS signaling pathways ［J］. Peptides， 2020， 124： 170212. doi:10.1016/j.peptides.2019.170212 |
| 8 | LI J， ALBAJRAMI O， ZHUO M， et al. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease ［J］. Clin J Am Soc Nephrol， 2020， 15（11）： 1678-1688. doi:10.2215/cjn.02690320 |
| 9 | WITHAAR C， MEEMS L M G， MARKOUSIS-MAVROGENIS G， et al. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction ［J］. Cardiovasc Res， 2021， 117（9）： 2108-2124. doi:10.1093/cvr/cvaa256 |
| 10 | GROUP G S R， NATHAN D M， LACHIN J M， et al. Glycemia Reduction in Type 2 Diabetes-Microvascular and Cardiovascular Outcomes ［J］. N Engl J Med， 2022， 387（12）： 1075-1088. doi:10.1056/nejmoa2200436 |
| 11 | TRANG N N， CHUNG C C， LEE T W， et al. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats ［J］. Int J Mol Sci， 2021， 22（3）： 1177. doi:10.3390/ijms22031177 |
| 12 | LI R， SHAN Y， GAO L， et al. The Glp-1 Analog Liraglutide Protects Against Angiotensin Ⅱ and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling ［J］. Front Pharmacol， 2019， 10： 537. doi:10.3389/fphar.2019.00537 |
| 13 | WANG J， GUO R， MA X， et al. Liraglutide inhibits AngⅡ-induced cardiac fibroblast proliferation and ECM deposition through regulating miR-21/PTEN/PI3K pathway ［J］. Cell Tissue Bank， 2023， 24（1）： 125-137. doi:10.1007/s10561-022-10021-9 |
| 14 | PRIMER K R， PSALTIS P J， TAN J T M， et al. The Role of High-Density Lipoproteins in Endothelial Cell Metabolism and Diabetes-Impaired Angiogenesis ［J］. Int J Mol Sci， 2020， 21（10）： 3633. doi:10.3390/ijms21103633 |
| 15 | 石建梅， 王茜茜， 韦晓洁. 铁蛋白自噬在糖尿病及其相关并发症发病机制中的研究进展 ［J］. 实用医学杂志， 2024， 40（3）： 417-422. |
| 16 | EL-ASHMAWY H M， SELIM F O， HOSNY T A M， et al. Association of low serum Meteorin like （Metrnl） concentrations with worsening of glucose tolerance， impaired endothelial function and atherosclerosis ［J］. Diabetes Res Clin Pract， 2019， 150： 57-63. doi:10.1016/j.diabres.2019.02.026 |
| 17 | PONT C， ASCASO F J， GRZYBOWSKI A， et al. Corneal endothelial cell density during diabetes mellitus and ocular diabetes complications treatment ［J］. J Fr Ophtalmol， 2020， 43（8）： 794-798. doi:10.1016/j.jfo.2019.12.003 |
| 18 | 林丹红，全会标，欧倩滢，等. 利拉鲁肽对超重或肥胖男性2型糖尿病患者睾酮及性功能的影响 ［J］. 实用医学杂志， 2023， 39（7）： 894-898. |
| 19 | 任丽君，高红红，宋瑞捧. 胰高血糖素样肽1受体基因遗传变异对利拉鲁肽治疗2型糖尿病患者疗效的影响 ［J］. 实用医学杂志， 2023， 39（2）： 164-169. doi:10.3969/j.issn.1006-5725.2023.02.007 |
| 20 | YAO Y， SONG Q， HU C， et al. Endothelial cell metabolic memory causes cardiovascular dysfunction in diabetes ［J］. Cardiovasc Res， 2022， 118（1）： 196-211. doi:10.1093/cvr/cvab013 |
| 21 | BAHADORAN Z， MIRMIRAN P， GHASEMI A， et al. Type 2 Diabetes and Cancer： The Nitric Oxide Connection ［J］. Crit Rev Oncog， 2019， 24（3）： 235-242. doi:10.1615/critrevoncog.2019031256 |
| 22 | CHEN W H， CHEN C H， HSU M C， et al. Advances in the molecular mechanisms of statins in regulating endothelial nitric oxide bioavailability： Interlocking biology between eNOS activity and L-arginine metabolism ［J］. Biomed Pharmacother， 2024， 171： 116192. doi:10.1016/j.biopha.2024.116192 |
| 23 | ALCAZAR-LEYVA S， ZAPATA E， BERNAL-ALCANTARA D， et al. Thiamine pyrophosphate diminishes nitric oxide synthesis in endothelial cells ［J］. Int J Vitam Nutr Res， 2021， 91（5/6）： 491-499. doi:10.1024/0300-9831/a000650 |
| 24 | BONDI C D， HARTMAN HLTAN R J. NRF2 in kidney physiology and disease ［J］. Physiol Rep， 2024， 12（5）： e15961. doi:10.14814/phy2.15961 |
| 25 | ZHANG Q， LIU J， DUAN H， et al. Activation of Nrf2/HO-1 signaling： An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress ［J］. J Adv Res， 2021， 34： 43-63. doi:10.1016/j.jare.2021.06.023 |
| 26 | YAN X， SU Y， FAN X， et al. Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism ［J］. Cells， 2022， 11（23）： 3821. doi:10.3390/cells11233821 |
/
| 〈 |
|
〉 |